Before market open, Cantor Fitzgerald prognosticator Steve Seedhouse flagged Lexicon as an overweight (buy, in other words) ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) said the FDA has declined to approve its drug Zynquista, also known as sotagliflozin, as an adjunct to insulin therapy for glycemic control in adults with type 1 ...
The analyst fair value estimate for Lexicon Pharmaceuticals has shifted from US$3.77 to US$4.55 per share, reflecting a higher modeled upside in the latest work. Recent Street commentary links this ...
Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second ...
Tom Garner is excited by Lexicon Pharmaceuticals' late-stage pipeline drug LX9211 to market for diabetic peripheral neuropathic pain. (aydinynr/iStock/Getty Images Plus) Lexicon Pharmaceuticals spent ...
“Total revenues were $21.1 million for the quarter… [including] 2 $10 million milestones recognized from the Novo Nordisk agreement and net sales of INPEFA of $1.1 million.” (Senior VP & CFO Scott ...
Lexicon Pharmaceuticals operates as a contender among biotech stocks by utilizing gene science to develop treatments for chronic conditions. The company primarily focuses on its commercial product, ...
Lexicon's Type 1 diabetes drug sotagliflozin is approved in Europe, but the company has had no luck convincing the FDA its safety issues can be mitigated. (Photo by Sarah Silbiger/Getty Images) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results